Shots:

• The P-III MYSTIC Trial involves assessing of Imfinzi (durvalumab) as a monothx or Imfinzi plus tremelimumab vs SoC Pt-based CT in patients with EGFR and anaplastic lymphoma kinase (ALK) wild-type- locally-advanced or metastatic Stage IV NSCLC in 167 centers across 17 countries
• MYSTIC Trial included 1EPs as PFS for combination and OS for monothx and demonstrated unmet 1EPs in the trial but showed tolerability consistency with no new safety issues
• Imfinzi is a mAb- which binds to PD-L1 while blocking its interaction with PD-1 and CD80 approved by the US FDA & EU for unresectable Stage III NSCLC. Tremelimumab is a mAb- targeting CTLA-4 (cytotoxic T-lymphocyte-associated protein 4)

Ref: AstraZeneca | Image: AstraZeneca